Publications by authors named "A R Guidi"
Article Synopsis
- The study examined how full vaccination and the timing of vaccinations affected SARS-CoV-2 infection rates among healthcare workers (HCWs) in Italy's Marche Region.
- 81.2% of HCWs in the cohort were fully vaccinated, with factors such as age, role, and prior health status influencing vaccination rates.
- Vaccination reduced infection risk by 77%, particularly for those vaccinated earlier, highlighting the need for effective vaccination strategies for all HCWs.
Background: In resectable gastric/gastroesophageal junction adenocarcinoma, microsatellite instability-high (MSI-H) confers improved survival, but limited benefit from chemotherapy. Immunotherapy may eliminate the need for chemotherapy or surgery.
Patients And Methods: INFINITY is a multicenter, multicohort phase II trial (NCT04817826) investigating in cohort 1 the activity and safety of tremelimumab + durvalumab (T300/D) as neoadjuvant treatment of mismatch repair deficient/MSI-H, resectable gastric/gastroesophageal junction adenocarcinoma.
This study aimed to investigate the antibacterial mechanism of atmospheric cold plasma (ACP) against Pseudomonas fluorescens and Pseudomonas putida and its preservation effect on red shrimp paste. A reactive species (RS) assay showed that O, HO, and total nitric oxide were generated after ACP treatment, which possessed great potential for antibacterial and food preservation. In vitro antibacterial results showed that excess RS inhibited bacterial activity through cell membrane damage.
View Article and Find Full Text PDFAmong neuroendocrine neoplasms (NENs), a non-negligible proportion (9-22%) is represented by sufferers of NENs of unknown primary origin (UPO), a poor prognostic group with largely unmet clinical needs. In the absence of standard therapeutic algorithms, current guidelines suggest that the treatment of UPO-NENs should be based on tumor clinical-pathological characteristics, disease burden, and patient conditions. Chemotherapy represents the backbone for the treatment of high-grade poorly differentiated UPO-NENs, usually providing deep but short-lasting responses.
View Article and Find Full Text PDFArticle Synopsis
- PROACT 2.0 is an open-source mobile and web application designed to improve communication between cancer patients and healthcare providers during clinical trials.
- Developed by Fondazione IRCCS Istituto Nazionale Tumori in Milan and The Christie in Manchester, it is part of the UpSMART Accelerator project involving various oncology centers in Europe.
- The app allows patients to report side effects and adverse events using text, audio, and video, creating a secure communication channel that enhances patient engagement and streamlines information management in cancer treatment.